ABSTRACT Detection and characterization of focal lesions in the cirrhotic liver may pose a diagnostic dilemma. Several benign and malignant lesions may be found in a cirrhotic liver along with hepatocellular carcinoma (HCC), and may exhibit typical or atypical imaging features. In this pictorial essay, we illustrate computed tomography and magnetic resonance imaging findings of lesions such as simple bile duct cysts, hemangioma, focal nodular hyperplasia-like nodules, peribiliary cysts, intrahepatic cholangiocarcinoma, lymphoma, and metastases, all of which occur in cirrhotic livers with varying prevalences. Pseudolesions, such as perfusion anomalies, focal confluent fibrosis, and segmental hyperplasia, will also be discussed. Imaging characterization of non-HCC lesions in cirrhosis is important in formulating an accurate diagnosis and triaging the patient towards the most appropriate management.
T he detection and characterization of focal lesions in a cirrhotic liver on computed tomography (CT) and magnetic resonance imaging (MRI) is a challenging task due to the marked changes in the organ architecture. Although hepatocellular carcinoma (HCC) is the most frequent primary tumor arising in a cirrhotic liver, several other benign and malignant lesions may be encountered in this setting (1, 2) . It is thus not surprising that CT and MRI have limited specificity for the diagnosis of HCC in cirrhosis.
Imaging characterization of focal lesions in cirrhosis is of the utmost importance for appropriate patient management. The radiologist's primary task is to maximize tumor detection (i.e., minimize false negatives), because missing the diagnosis of HCC may preclude potentially curative therapies, such as hepatic resection, percutaneous ablation procedures, and, in selected patients, liver transplantation. However, it is equally important to avoid the misdiagnosis of benign liver lesions as HCC (i.e., minimize false positives) because this diagnostic interpretation may incorrectly increase the tumor burden. This may also result in the ineligibility of the patient for potentially curative treatments or the inappropriate assignment of increased priority scores for patients on the waiting list for liver transplantation. In this paper, we discuss and illustrate CT and MRI features of both common and uncommon non-HCC liver lesions occurring in cirrhotic patients.
Focal lesions beyond hepatocellular carcinoma in cirrhotic liver
A wide spectrum of benign and ma lignant lesions other than HCC may be encountered in the cirrhotic liver. Familiarity with the imaging findings of these lesions may be helpful for radiologists for precise diagnosis and appropriate management. The Table summarizes the incidence and frequency of imaging features of focal liver lesions occurring in the cirrhotic and noncirrhotic liver.
Benign lesions
Hemangioma is seen less frequently in cirrhotic patients than in the general population (3) . There are two main challenges in the diagnosis of hemangioma in cirrhosis. The first is that of a capillary hemangioma, also commonly referred to as a flash-filling hemangioma. The differential diagnosis with small hypervascular HCC is based on the differing enhancement patterns. Although both lesions will typically show hypervascularity in the hepatic arterial phase, flash-filling hemangiomas demonstrate strong and homogeneous attenuation, typically matching the enhancement of the aorta during the hepatic arterial phase (Fig. 1a) , and of the intrahepatic veins during the hepatic venous phase (Fig. 1b) .
This enhancement pattern differs significantly from that of HCC, where tumor enhancement during the hepatic arterial phase is typically milder and followed by washout during the hepatic venous and delayed phases (i.e., tumor hypoattenuation/intensity compared with the surrounding liver parenchyma). In small HCC, washout may be absent (Fig. 2) , likely because of conservation of the portal blood supply, thus making the tumor appear isoattenuating/isointense to the surrounding liver parenchyma (4) . This appearance may pose a diagnostic challenge for the differential diagnosis with a small capillary hemangioma.
The second scenario is when the fibrotic and scarring processes distort liver architecture, also causing a fibrotic involution of the lesion. In such cases, hemangiomas are typically hypovascular, losing features commonly observed in noncirrhotic livers, such as globular peripheral enhancement patterns and isointensity to vessels on multiphasic imaging (Fig. 3) (3) . It is our anecdotal observation that in these instances, differential diagnosis with those HCC referred to as "hypovascular," because of the lack of enhancement in the hepatic arterial phase, will be based on lesion shape and attenuation. Hypovascular HCC is a spherical lesion, slightly hypoattenuating, and therefore recognizable, versus the surrounding liver in the venous phase (Fig. 4) , while fibrotic hemangiomas commonly have an irregular shape and more pronounced hypoattenuation in comparison with the surrounding liver on unenhanced and postcontrast images (Fig. 3b) . Furthermore, strong hyperintensity on T2-weighted MR images remains helpful information for the more confident characterization of atypical hemangiomas in cirrhotic livers.
While a few case reports have described focal nodular hyperplasia-like nodules in the cirrhotic liver (5-7), in our experience, this coexistence is exceedingly rare. These nodules are usually small (<2 cm) and share several imaging and histological features with focal nodular hyperplasia arising in noncirrhotic patients, including homogeneous hypervascularity in the hepatic arterial phase, and a central stellate scar-like fibrosis. Focal nodular hyperplasia will typically show fading to isoattenuation in the hepatic venous phase, thus showing overlapping features with hypervascular dysplastic nodules and small well-differentiated HCC (Fig. 5 ). These similarities in imaging create difficulties in the differential diagnosis and may lead to unnecessary treatment. MR contrast agents with combined vascular and delayed hepatobiliary excretion, such as gadobenate dimeglumine (Multihance, Bracco, Milano, Italy) and gadolinium ethoxybenzyl dimeglumine (Primovist, Bayer, Berlin, Germany) suggest a diagnosis of HCC when showing hypointensity in the hepatobiliary phase. However regenerative nodules, dysplastic nodules, focal nodular hyperplasia-like lesions (Fig. 6 ), and about 10% of HCC can all show hyperintensity in the hepatobiliary phase (8, 9) . Thus, hyperintensity alone does not allow a specific diagnosis.
We have never observed hepatocellular adenoma in cirrhosis. In the literature, few reports describe the association (10, 11) .
Simple biliary cysts have similar features in cirrhotic and noncirrhotic livers: low attenuation on CT, low signal intensity on T1-weighted MR sequences, and high signal on heavily T2-weighted MR sequences, with no contrast enhancement (Fig. 7) .
Peribiliary cysts are cystic lesions typically found on both sides of the intrahepatic portal venous branches, as opposed to intrahepatic biliary dilatation, which is located on one side only of portal venous branches. These lesions may have variable sizes and morphologies. They represent cystic dilatation of the extramural glands in the periductal connective tissue and show the same imaging findings as simple cysts (Fig. 8) (12) .
Malignant lesions
Intrahepatic cholangiocarcinoma is the second most common primary malignancy, after HCC, in both cirrhotic and noncirrhotic liver (13) . Liver cirrhosis is considered a risk factor not only for HCC development, but also for cholangiocarcinoma. In patients with cirrhosis, cholangiocarcinoma will typically be hypervascular when smaller than 3 cm, and this enhancement pattern is more common in patients with chronic liver disease versus patients with noncirrhotic livers (14, 15) . Thus, the differential diagnosis between small cholangiocarcinoma and HCC is difficult in the cirrhotic liver (Fig. 9a) . When larger than 3 cm, a peripheral enhancing rim, centripetal pattern, capsular retraction, and segmental biliary ductal dilatation will be major imaging features, resembling the classic CT findings of cholangiocarcinoma in the noncirrhotic liver (Fig. 9b, 9c) (16, 17) . In our experience, mixed hepatocellular-cholangiocarcinomas can occur in patients with chronic liver disease (18) . These tumors may show imaging features of both hepatocellular carcinoma and cholangiocarcinoma, so a confident diagnosis may not be possible on the basis of imaging alone.
An association between hepatitis C virus and non-Hodgkin B-cell lymphoma has been described by several authors (19) . Primary liver involvement is rare, and causes diffuse hepatic involvement, while secondary hepatic lymphoma is more common, and typically consists of multiple small nodules. On MRI, lymphomatous nodules are commonly hypointense on T1, hyperintense on T2, and have variable vascularity after gadolinium injection (Fig. 10a) . Because they do not contain functioning hepatocytes, they are hypointense in the hepatobiliary phase (Fig. 10b) , and due to high cellularity, they show signal restriction on high-B diffusion-weighted imaging (Fig. 10c) .
The rare occurrence of metastases in cirrhosis may be due to hepatofugal portal venous flow that prevents neoplastic cells from seeding and flourishing in the liver (20) . However, some primary neoplasms, such as colorectal adenocarcinoma, may infrequently spread to the liver in cirrhotic patients (21) . Typical imaging features of metastases occurring in cirrhosis include mild hyperintensity on T2-weighted images and ring enhancement in the hepatic arterial phase (Fig. 11) , although these findings may also be encountered in cholangiocarcinoma.
Pseudolesions: perfusion abnormalities
The distorted architecture of the hepatic parenchyma in advanced cirrhosis is a predisposing condition to the development of arterioportal shunting. These vascular derangements are commonly referred to as "pseudolesions". They are typically visible as focal areas of hyperenhancement on images acquired during the hepatic arterial phase, with no washout in the hepatic venous or delayed phases. Arterioportal shunts are usually wedge-shaped and subcapsular, they have no mass effect on adjacent vessels or bile ducts, and they do not grow at imaging follow-up. In MRI, these "pseudolesions" are isointense to the surrounding liver parenchyma on precontrast T1-and T2-weighted images, as well as on images acquired during the hepatobiliary phase after administration of gadobenate dimeglumine or gadolinium ethoxibenzyl diethylenetriamine pentaacetic acid (Fig. 12) . However, the specificity of these imaging findings does not allow reliable exclusion of small, well-differentiated HCC (Fig. 2) , especially when the hyperenhancing In the hepatobiliary phase, 20 min after Gd-EOB-DTPA administration, the lesion (arrow) was hyperintense. The lesion remained unchanged at follow-up performed two years later (not shown). Due to the stability in size and imaging features, this lesion was interpreted as a focal nodular hyperplasia-like nodule. Note contrast medium accumulation in the nondependent portion of the gallbladder, as typically observed in the hepatobiliary phase.
focus is round in shape (22) . The latest guidelines of the American Association for the Study of Liver Diseases (AASLD) recommend imaging follow-up for small indeterminate hyperenhancing nodules in a cirrhotic liver, to assess growth or change in imaging pattern (23) . At our institution, when we detect subcentimetric round enhancing indeterminate lesions, we perform ultrasonography follow-up at six months and CT or MRI follow-up at 12 months (24).
Fibrosis is always present to some degree in cirrhosis. In more advanced disease, fibrosis can appear as a focal, wedge-shaped area, radiating from the porta hepatis, widest at the capsular surface, with associated capsular retraction more frequently located in segments IV, VII, or VIII of the liver. This entity is known as focal confluent fibrosis. On contrast-enhanced CT or T1-weighted MRI, it usually appears hypoattenuating/hypointense compared with the surrounding liver parenchyma, and slightly hyperintense on delayed-phase images, because of contrast accumulation in the fibrotic tissue (Fig. 13) . Less frequently, focal confluent fibrosis may appear hypervascular in the arterial phase without a clear wedge shape or associated capsular retraction, thus potentially resembling HCC (25, 26) . Segmental or lobar hyperplasia is observed in end-stage cirrhosis, typically secondary to sclerosing cholangitis, although it can also be observed in the setting of alcoholic cirrhosis. It is due to the pseudotumoral enlargement of one or more segments, along with atrophy of the peripheral hepatic segments, and results in a lobulated liver contour (Fig. 14) (27) .
Conclusion
A wide spectrum of benign and malignant lesions other than HCC may be found in the cirrhotic liver. MRI should be preferred over CT as the primary imaging modality for the evaluation of cirrhotic patients due to its greater ability to detect and characterize focal lesions. When a lesion lacks the typical features of HCC (hyperenhancement in the arterial phase and hypoenhancement-washout-in the venous and/or Figure 12 . a-c. A 63-year-old male with hepatitis C-related cirrhosis and a pseudolesion in segment VII. Hepatic arterial phase fat-saturated volumetric T1-weighted image (a) shows nodular, arterial hyperenhancement (arrow) in segment VII. On hepatic venous (b) and hepatobiliary (c) fat-saturated volumetric T1-weighted images, the lesion was not visible. Due to its stability over one year and the lack of hypointensity in the hepatobiliary phase, it was interpreted as a pseudolesion, although these imaging features are also compatible with a dysplastic nodule. delayed phase), the radiologist should consider performing follow-up or a biopsy to pursue the correct diagnosis.
